Chronic kidney disease (CKD) represents a global public health concern and results in poor health outcomes. While the burden of CKD is accurately well defined in developed countries, increasing evidence indicates that the CKD burden may be even greater in developing countries. Primary care has an essential role in the early identification of CKD and the prompt integrated management between primary and secondary CKD care, with participation of the patient, should be done in high quality. Systematic screening for CKD in at-risk individuals is strongly indicated for timely intervention when needed and to perceive the impact of such policies on CKD incidence. Furthermore, failure to recognize a patient in stages 1-3 of CKD may result in high incidence of CKD complications and kidney failure, often leaving the patient unsuitable for different renal replacement therapies, such as dialysis and transplantation. Therefore, primary care early referral and consultation with a nephrologist can give a better chance for different dialysis procedures and minimize the rate of hospitalization and mortality.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10641963.2021.1896726DOI Listing

Publication Analysis

Top Keywords

ckd
9
chronic kidney
8
kidney disease
8
primary care
8
screening early
4
early detection
4
detection chronic
4
primary
4
disease primary
4
primary healthcare
4

Similar Publications

Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.

Nephrol Dial Transplant

November 2024

Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).

Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).

View Article and Find Full Text PDF

Introduction: Chronic Kidney Disease (CKD) is recognized as a major global public health problem. Dialysis is the mainstay of treatment for patients with end-stage renal disease and can prolong survival in patients with CKD. As patient survival increases, the treatment of complications becomes more important.

View Article and Find Full Text PDF

Background: Chronic kidney disease (CKD) increases cardiac arrest (CA) risk because of renal and cardiovascular interactions.

Methods: Using Centers for Disease Control and Prevention (CDC) data from 1999 to 2020, we analyzed CKD-related CA mortality and the impact of social vulnerability index (SVI).

Results: We identified 336 494 CKD-related CA deaths, with stable age-adjusted mortality rates over time.

View Article and Find Full Text PDF

Erythroferrone (ERFE) has emerged as a potential biomarker for the erythropoiesis response following recombinant human erythropoietin (rHuEPO) treatment. While the association between ERFE and hemoglobin (HGB) response to rHuEPO is well-established in nonanemic conditions, such correlation and ERFE kinetics in anemic states remain unclear. We employed two rat models of anemia, chronic kidney disease (CKD) anemia and chemotherapy-induced anemia (CIA), to determine ERFE kinetics and its correlation with HGB responses after rHuEPO administration.

View Article and Find Full Text PDF

This study conducts a bibliometric analysis (BA) to map the research landscape surrounding chronic kidney disease (CKD) and iron overload over the past decade. Utilizing PubMed as the primary database, a systematic search strategy was developed using BA guidelines, incorporating keyword and MeSH term refinements for comprehensive data retrieval. A Boolean operator-based search strategy was applied, capturing literature from 2014 to the first quarter of 2024, with inclusion criteria focusing on articles and review articles published in English.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!